Congratulations, hepatitis C patients in BC, BC PharmaCare, and AbbVie Pharmaceuticals! One more treatment option is now available to BC HCV patients of all genotypes, New patients without cirrhosis need only 8 weeks treatment. Maviret™ is also safe and effective for the many HCV+ people with chronic kidney disease (CKD). More information: https://www.newswire.ca/news-releases/british-columbia-pharmacare-lists-abbvie-s-hepatitis-c-treatment-mavi...
We've been asked by CADTH* to do a Patient Group Review of the new INTERFERON-FREE 3-drug combo ombitasvir (ABT-267), paritaprevir (ABT-450)+ritonavir, and dasubuvir (ABT-333) which was developed for Chronic Hepatitis C by pharmaceutical company, AbbVie. We urgently request input from individual HCV+ people with any genotype (both those who have and have not tried this drug combination). For background info see http://hepcbc.ca/contribute-to-abbvie-3d-su
On Sept. 8, 2014, Dr. Paul Marotta of London Health Sciences Centre, presented "Transformation of HCV Management: The IFN-free Era". To access a PDF of this highly-informative and "up-to-the-minute" presentation, click HERE: DrPaulMarotta_20140908_HCV_Treatment_Presentation. Many thanks, Dr. Marotta, for generously sharing these excellent materials with HepCBC's online members.
Bangkok, Thailand, Feb. 28, 2014 (press release): "Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies. Yet AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche refused to provide a plan for equitable access to treatment for HCV, a curable infection t
An HCV+ member of HepCBC was asked to give a 10-minute speech at CATIE (Canadian AIDS Treatment Information Exchange) last week about what sort of policies HCV+ people hoped would come about in the next 5 years. Lots of illustrations/images. Here is the speech: VIDEO: http://www.catie.ca/en/forum/webcast-archive/closing-plenary#reitz PDF: http://www.hcvadvocate.org/community/community_pdf/HepCBC_CATIE_2013.pdf